e a b c d unstimulated +fMLP T308P-Akt S473P-Akt Akt (min) 0 0.5 1 1.5 2 4 + fMLP (100 nM) PH-Akt-GFP Anti-PIP3 antibody Figure 1a-e, supplement

f (min) 0.5 1 1.5 2 4 + fMLP (100 nM) Figure 1f, supplement

a b DiD Overlay PH-Akt-GFP Ratio (PH-Akt-GFP/DiD) Fig. 2a-b, supplement

c Fig. 2c, supplement

a HL-60 + 50 nM wort Figure 3a, supp

b d c + 200 nM wort T308P-Akt S473P-Akt Akt HL-60 + 50 mM LY 120 100 80 Relative level of T308P-Akt (%) 60 + 200 nM wort 40 c 20 120 T308P-Akt 100 80 S473P-Akt Relative level of S473P-Akt (%) 60 40 Akt 20 HL-60 1 2 3 4 5 6 7 + 50 mM LY HL-60 +fMLP + 20 nM wort + 50 nM wort + 200 mM LY + 400 mM LY HL-60 + 200 nM wort + 50 mM LY + 20 nM wort + 50 nM wort + 200 mM LY + 400 mM LY + 200 nM wort Figure 3b-d, supplement

a b c HL-60 + wort 2 min 6 min 10 min Paths HL-60 + wort HL-60 HL-60 + fMLP 150 HL-60 100 50 3 1 2 4 HL-60 HL-60 + wort + 50 nM wort + 200 nM wort Figure 4, supplement

a b c Cell Number Log [fMLP] (nM) PLB-985 + 30 nM wortmannin 4000 Cell Number 2000 0.1 1 10 100 Human blood neutrophils Log [fMLP] (nM) c PLB-985 + 200 mM LY 294002 + 30 nM wortmannin Figure 5, supplement